Fresh Tracks Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Fresh Tracks Therapeutics has a total shareholder equity of $9.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $11.6M and $1.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$10.87m |
Equity | US$9.93m |
Total liabilities | US$1.66m |
Total assets | US$11.59m |
Recent financial health updates
Recent updates
Brickell Biotech changes name to Fresh Tracks Therapeutics
Sep 07Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M
Aug 11Brickell Biotech regains Nasdaq compliance for minimum bid price requirement
Jul 20Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely
Feb 14Brickell Biotech Advances To Phase III As It Eyes Commercialization
May 10Brickell Biotech completes patient enrollment in late-stage sweat disorder study
Apr 27Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.
Jan 06Brickell Biotech (BBI) Investor Presentation - Slideshow
Dec 02Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26
Nov 18Financial Position Analysis
Short Term Liabilities: FRTX's short term assets ($11.6M) exceed its short term liabilities ($1.7M).
Long Term Liabilities: FRTX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: FRTX is debt free.
Reducing Debt: FRTX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if FRTX has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if FRTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 12:35 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2023/12/31 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fresh Tracks Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Raghuram Selvaraju | H.C. Wainwright & Co. |
Thomas Flaten | Lake Street Capital Markets, LLC |
Leland Gershell | Oppenheimer & Co. Inc. |